Q2 revenue rises 39%, but net loss persists at Rs 539.85 lakh

Revenue Growth 20pctPat NegativeResults View source PDF Explain this filing

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹58.51

prior close

₹59.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-1.5% vs market

Pharmaceuticals peers, median of 171sector+0.4%-1.2% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+0.7-1.5+0.4-1.2

Next day

-3.4pendingpending-0.6-2.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the September 2026 quarter, revenue rose 39% to Rs 579.03 lakh, while net loss narrowed 12% to Rs 539.85 lakh. In the first half, revenue rose 32% to Rs 1,277.38 lakh and loss narrowed 31% to Rs 788.33 lakh. Operating cash flow was positive at Rs 299.78 lakh. The Vizag unit remains closed since February 2025.

Likely market impact

Better sales and positive cash flow offer some support, but continued losses and the closed Vizag plant may keep the stock under pressure.